Palmitoylcarnitine (chloride)

Palmitoylcarnitine chloride is a fatty acid-derived mitochondrial substrate, and selectively decreases cell survival in colorectal and prostate cancer cells by affecting on pro-inflammatory pathways, Ca2+ influx, and DHT-like effects[1].

Product Specifications

CAS Number

[6865-14-1]

UNSPSC

12352211

Hazard Statement

H302, H312, H332

Target

Akt; Calcium Channel; Endogenous Metabolite

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling; PI3K/Akt/mTOR

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/palmitoylcarnitine-chloride.html

Purity

98.0

Solubility

DMSO : 8.33 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 50 mg/mL (ultrasonic)

Smiles

CCCCCCCCCCCCCCCC(OC(CC(O)=O)C[N+](C)(C)C)=O.[Cl-]

Molecular Formula

C23H46ClNO4

Molecular Weight

436.07

Precautions

H302, H312, H332

References & Citations

[1]Al-Bakheit A, et al. Accumulation of Palmitoylcarnitine and Its Effect on Pro-Inflammatory Pathways and Calcium Influx in Prostate Cancer. Prostate. 2016 Oct;76 (14) :1326-37.|[2]Netticadan T, et al. Palmitoyl carnitine increases intracellular calcium in adult rat cardiomyocytes. J Mol Cell Cardiol. 1999 Jul;31 (7) :1357-67.|[3]Liepinsh E, et al. Acute and long-term administration of palmitoylcarnitine induces muscle-specific insulin resistance in mice. Biofactors. 2017 Sep 10;43 (5) :718-730.